Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer

Thomas Michael, Fischer Jürgen, Andreas Stefan, Kortsik Cornelius, Grah Christian, Serke Monika, von Eiff Michael, Witt Christian, Kollmeier Jens, Müller Ernst, Schenk Michael, Schröder Michael, Villalobos Matthias, Reinmuth Niels, Penzel Roland, Schnabel Philipp, Acker Thomas, Reuss Alexander, Wolf Martin

Source: Eur Respir J 2015; 46: 219-229
Journal Issue: July
Disease area: Thoracic oncology

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Thomas Michael, Fischer Jürgen, Andreas Stefan, Kortsik Cornelius, Grah Christian, Serke Monika, von Eiff Michael, Witt Christian, Kollmeier Jens, Müller Ernst, Schenk Michael, Schröder Michael, Villalobos Matthias, Reinmuth Niels, Penzel Roland, Schnabel Philipp, Acker Thomas, Reuss Alexander, Wolf Martin. Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer. Eur Respir J 2015; 46: 219-229

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002

Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004

Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009

Gemcitabine, ifosfamide and paclitaxel in patients with untreated advanced/metastatic nonsmall cell lung cancer (NSCLC) A phase II study
Source: Eur Respir J 2003; 22: Suppl. 45, 28s
Year: 2003

Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 64s
Year: 2003

First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial
Source: Eur Respir J, 56 (2) 1902066; 10.1183/13993003.02066-2019
Year: 2020



Second-line weekly docetaxel in advanced non-small cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 377s
Year: 2001

Non-small cell lung cancer treatment: chemotherapy combination gemcitabine – cisplatin – paclitaxel
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004

Second-line weekly paclitaxel in advanced nonsmall cell lung cancer (NSCLC)
Source: Annual Congress 2003 - Advanced lung cancer treatment
Year: 2003


Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006

Chemotherapy with carboplatin and gemcitabine in patients with non resectable stages of non-small cell lung cancer (non-SCLC)
Source: Eur Respir J 2007; 30: Suppl. 51, 436s
Year: 2007

A phase II study of docetaxel in combination with carboplatin in the treatment of non-small cell lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 186s
Year: 2002

A randomised prospective trial of concurrent chemoradiotherapy (CCRT) with cisplatin and paclitaxel or docetaxel or gemcitabine in stage IIIB nonsmall cell lung cancer
Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer
Year: 2009



Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013

Weekly chemotherapy with cisplatin and paclitaxel in inoperable advanced non-small cell lung cancer: an extended phase II study
Source: Eur Respir J 2005; 26: Suppl. 49, 12s
Year: 2005

Combination of erlotinib and bevacizumab in non small cell lung cancer patients
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012

The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease.
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017



Consolidation maintenance oral vinorelbine following concurrent chemoradiation of intravenous vinorelbine and cisplatin in patients with unresectable stage III non-small cell lung cancer
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015

Gemcitabine and cisplatin ( GD) as first line chemotherapy in patients with non-small-cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002

Non-small cell lung cancer - oral navelbine single-agent chemotherapy in elderly patient advanced stage or metastatic disease
Source: Eur Respir J 2004; 24: Suppl. 48, 303s
Year: 2004